Articles

Posted: 29/10/2009

The vaccine market has evolved rapidly in the past decade. Marcel Thalen, of SynCo Bio Partners, looks at the changes from a manufacturer's perspective.

Posted: 19/10/2009

The biopharmaceutical contract manufacturing (CMO) industry has experienced a significant improvement in the average expression levels for both mammalian cell culture and microbial fermentation, according to the “Biopharmaceutical Contract Manufacturing 2009: Expanding Markets, New Capacities and Improved Performance” report recently published by HighTech Business Decisions.

Posted: 14/10/2009

THE CHALLENGES of vaccine development go well beyond the mathematics of mass production. For a relatively mild disease, swine flu, or H1N1, has demonstrated the pharmaceutical industry's limitations when it comes to producing vaccines for the global population.

Posted: 09/06/2009

SynCo Bio Partners believe that contract manufacturing should not be “one size fits all” and that the biopharmaceutical contract manufacturing industry needs to explore different collaborative business models in the development of production processes with prospective clients.

Posted: 05/11/2008

In September 2006, Cleveland BioLabs Inc. approached SynCo with a challenge – could they help to develop a production process, scale up, and manufacture a cGMP batch of their recombinant protein treatment for exposure to radiation (Protectan CBLB502) in approximately a year?

Posted: 02/09/2008

Combined advances in molecular biology, cell biology, and genomics have led to a wealth of new information about cellular processes. A growing understanding of the fundamentals of cell biology is now being translated into products that use an approach to exert a biological effect that is different from that of most biologicals currently on the market.

Posted: 31/05/2008

p22-25 Joanne McCudden, director of sales & marketing, and Marcel Thalen, scientific officer of SynCo Bio Partners, discuss with Tom Mulligan the benefits of using CMO services in moving biopharmaceuticals through the development pipeline to commercial production.

Posted: 25/05/2008

SynCo Bio Partners has completed production of AG011 for ActoGenIX, enabling the latter firm to begin examining it in patients suffering from ulcerative colitis (UC).

Posted: 24/05/2008

Contract Pharma

Posted: 10/03/2008

CLEVELAND BIOLABS (CBL) is a typical virtual biopharmaceutical firm. With a cancer therapy in Phase II clinical trials, and a radiation protection and mitigation drug currently before the Department of Defense, it employs a network of contract service firms around the world.